TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Press Releases > PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger

PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger

Merger strengthens market access expertise  

 

Frankfurt, Germany – March 9, 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with Italy-based EBMA Consulting, a specialist consultancy company focused on strategic pricing, market access and health economics services for the life sciences.

Founded in 2010 by Gianluca Furneri, EBMA Consulting has many years of practical experience in health economics, pricing and market access and serves small and mid-sized pharmaceutical companies in Italy as well as  the rest of Europe and the U.S.

EBMA Consulting specializes in offering general market access insights, providing market access development strategies and supporting customers with communicating the value of their products through health technology assessments to key stakeholders.  

“The merger with PharmaLex creates the opportunity to provide a Europe-wide market access platform within PharmaLex, while also paving the way to developing a global community in market access,” Gianluca said. “With our shared commitment to solutions to meet the challenges our clients face, the merger between EBMA Consulting and PharmaLex will help clients address the pricing and reimbursement challenges they often face when negotiating with payers. I am very happy to join and support PharmaLex’s group of consultants to expand the combined market access service offering.” 

“We are delighted to welcome Gianluca and his incredibly talented team of experts to the PharmaLex Group.  Together with PharmaLex Italy and MA Provider, another recent merger, EBMA strengthens our market access services to provide comprehensive, strategic and operational support, to successfully secure market access in the EU and set the basis to reach their commercial objectives,” said PharmaLex CEO Dr. Thomas Dobmeyer. “EBMA has an outstanding track record developing bespoke approaches to meet the market access requirements of clients, supported by solid analytical capabilities. This approach fits seamlessly with our vision and values at PharmaLex to always provide quality services and outstanding solutions to exceed our customers’ expectations.”  

Suspendisse facilisis neque a sem faucibus, nec porttitor dolor vulputate. Maecenas aliquam justo enim, id dapibus eros pretium a. Nulla sit amet lectus at leo luctus varius non et urna. In quis felis tristique, posuere lectus vitae, ultrices neque. Aliquam sit amet turpis ut dui feugiat dignissim. Donec at nisi tellus. Nulla auctor commodo porttitor.

Related posts
PharmaLex extends reach to Japan, East Asia and Southeast Asia with Ascent Development Services merger
PharmaLex extends reach to Japan, East Asia and Southeast Asia with Ascent Development Services merger
8th February 2022
PharmaLex expands global footprint capabilities for clinical and regulatory services with Phlexglobal merger
PharmaLex expands global footprint capabilities for clinical and regulatory services with Phlexglobal merger
25th January 2022
PharmaLex merger with MAP Group expands integrated market access expertise
PharmaLex merger with MAP Group expands integrated market access expertise
18th January 2022
Pharma time-to-market reduced thanks to more efficient submission document publishing services
Pharma time-to-market reduced thanks to more efficient submission document publishing services
11th January 2022
PharmaLex extends footprint for technology-enabled smart services with new strategic partnership
PharmaLex extends footprint for technology-enabled smart services with new strategic partnership
7th December 2021
PharmaLex expands technology-enabled solution portfolio with integration of software platforms
PharmaLex expands technology-enabled solution portfolio with integration of software platforms
30th November 2021
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
20 May

PharmaLex is excited to be supporting the #ARCSannualconference again this year. Be sure to join their sessions and visit our team at stand 44.

Find out more: https://lnkd.in/g6fbC2kr

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Worked with us and our contractors to help us achieve our tight targets, operate with our systems and procedures and are considered invaluable part of our team

    US based large development group
    VP Regulatory / Quality
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for